Literature DB >> 21685924

Highlights on FOXO3 and tumor-associated dendritic cells in prostate cancer.

Kwong Y Tsang1, James L Gulley.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21685924      PMCID： PMC3739599          DOI： 10.1038/aja.2011.78

Source DB:  PubMed          Journal:  Asian J Androl        ISSN： 1008-682X            Impact factor:   3.285


× No keyword cloud information.
  10 in total

1.  Analysis of circulating regulatory T cells in patients with metastatic prostate cancer pre- versus post-vaccination.

Authors:  Matteo Vergati; Vittore Cereda; Ravi A Madan; James L Gulley; Ngar-Yee Huen; Connie J Rogers; Kenneth W Hance; Philip M Arlen; Jeffrey Schlom; Kwong Y Tsang
Journal:  Cancer Immunol Immunother       Date:  2010-10-26       Impact factor: 6.968

Review 2.  Regulatory T cells in ovarian cancer: biology and therapeutic potential.

Authors:  Brian Barnett; Ilona Kryczek; Pui Cheng; Weiping Zou; Tyler J Curiel
Journal:  Am J Reprod Immunol       Date:  2005-12       Impact factor: 3.886

3.  Sipuleucel-T immunotherapy for castration-resistant prostate cancer.

Authors:  Philip W Kantoff; Celestia S Higano; Neal D Shore; E Roy Berger; Eric J Small; David F Penson; Charles H Redfern; Anna C Ferrari; Robert Dreicer; Robert B Sims; Yi Xu; Mark W Frohlich; Paul F Schellhammer
Journal:  N Engl J Med       Date:  2010-07-29       Impact factor: 91.245

4.  Cancer statistics, 2010.

Authors:  Ahmedin Jemal; Rebecca Siegel; Jiaquan Xu; Elizabeth Ward
Journal:  CA Cancer J Clin       Date:  2010-07-07       Impact factor: 508.702

5.  FOXO3 programs tumor-associated DCs to become tolerogenic in human and murine prostate cancer.

Authors:  Stephanie K Watkins; Ziqiang Zhu; Elena Riboldi; Kim A Shafer-Weaver; Katherine E R Stagliano; Martha M Sklavos; Stefan Ambs; Hideo Yagita; Arthur A Hurwitz
Journal:  J Clin Invest       Date:  2011-03-23       Impact factor: 14.808

6.  CD4+CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients.

Authors:  Ashley M Miller; Kajsa Lundberg; Volkan Ozenci; Alison H Banham; Magnus Hellström; Lars Egevad; Pavel Pisa
Journal:  J Immunol       Date:  2006-11-15       Impact factor: 5.422

7.  Enhanced functionality of CD4+CD25(high)FoxP3+ regulatory T cells in the peripheral blood of patients with prostate cancer.

Authors:  Junko Yokokawa; Vittore Cereda; Cinzia Remondo; James L Gulley; Philip M Arlen; Jeffrey Schlom; Kwong Y Tsang
Journal:  Clin Cancer Res       Date:  2008-02-15       Impact factor: 12.531

Review 8.  Promising novel immunotherapies and combinations for prostate cancer.

Authors:  Philip M Arlen; Mahsa Mohebtash; Ravi A Madan; James L Gulley
Journal:  Future Oncol       Date:  2009-03       Impact factor: 3.404

9.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

Authors:  Ian F Tannock; Ronald de Wit; William R Berry; Jozsef Horti; Anna Pluzanska; Kim N Chi; Stephane Oudard; Christine Théodore; Nicholas D James; Ingela Turesson; Mark A Rosenthal; Mario A Eisenberger
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

10.  Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer.

Authors:  James L Gulley; Philip M Arlen; Ravi A Madan; Kwong-Yok Tsang; Mary P Pazdur; Lisa Skarupa; Jacquin L Jones; Diane J Poole; Jack P Higgins; James W Hodge; Vittore Cereda; Matteo Vergati; Seth M Steinberg; Susan Halabi; Elizabeth Jones; Clara Chen; Howard Parnes; John J Wright; William L Dahut; Jeffrey Schlom
Journal:  Cancer Immunol Immunother       Date:  2009-11-05       Impact factor: 6.968
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.